AbbVie announces €40 million investment in Sligo

Biopharmaceutical company to create 50 new jobs over next four years in Ballytivnan

AbbVie chief executive Rick Gonzalez and Taoiseach Enda Kenny at the official opening of the newly expanded AbbVie facility in Sligo last year.
AbbVie chief executive Rick Gonzalez and Taoiseach Enda Kenny at the official opening of the newly expanded AbbVie facility in Sligo last year.

AbbVie is to expand its medical device manufacturing facility in Sligo, creating 50 highly-skilled jobs over the next four years.

The biopharmaceutical company, which was formed in 2013 following separation from Abbott Laboratories, is investing €40 million in its manufacturing facility at Ballytivnan in Sligo.

The company’s manufacturing site in Ballytivnan currently produces drug delivery devices, including a pen-style injector that is used by patients around the world who use AbbVie’s treatment indicated for a range of auto-immune conditions.

Including today’s announcement, AbbVie’s investment in Ballytivnan and broader manufacturing operations in the country has reached more than €134 million since 2013.

READ SOME MORE

AbbVie employs more than 500 people at five different sites around the country, including three manufacturing plants – two in Sligo and one in Cork. The research-based biopharmaceutical company was formed in 2013 following separation from Abbott Laboratories.